Assess if a reduced dosing schedule of PCV13 (1+1) is non-inferior to the currently-used schedule (2+1) with regards to serotype-specific IgG concentration following booster dose at age 12 months. Outcome measures will be:
- Serotype-specific anti-pneumococcal IgG geometric mean concentration (GMC)
- Proportion of children achieving IgG ≥0.35 μg/ml at 1 month after (i) infant priming dose(s) and (ii) the age 12-month booster dose.
Dr. Manish Sadarangani